Mark Buyyounouski

Radiation oncologist

Radiation Oncology

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Urologic Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Internship: St Barnabas Medical Center (2001) NJ

Board Certification: Radiation Oncology, American Board of Radiology (2006)

Residency: Fox Chase Cancer Center (2005) PA

Medical Education: UMDNJ-NJMS (2000) NJ

Honors & Awards

RSNA Seed Grant, Radiological Society of North America Roentgen (RSNA) (2008)

Travel Grant to attend National Cancer Institute Radiation Research Program, American Society for Radiation Oncology (ASTRO) (2005)

Roentgen Resident/Fellow Research Award, Radiological Society of North America Roentgen (RSNA) (2003, 2005)

EXCEL Research Scholarship, Department of Physics, Lafayette College (1993)

Administrative Appointments

Member, Genitourinary Committee, American Board of Radiology, 2012

Chair, Committee for Evidence-Based Brachytherapy, American Brachytherapy Society, 2013

Secretary, American Brachytherapy Society, 2010

Treasurer, American Brachytherapy Society, 2011

Vice-Chair, Emerging Technology Committee, American Society for Radiation Oncology, 2011

Editor, Brachytherapy, 2013

Associate Senior Editor, International Journal of Radiation Oncology, Biology, and Physics, 2011

Director, Genitourinary Cancers, 2103

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Hospital & Clinics patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., & Buyyounouski, M. K. (2013). Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. Journal of clinical oncology , 31(31), 3860-3868.

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial
Mitin, T., Hunt, D., Shipley, W. U., Kaufman, D. S., Uzzo, R., & Zietman, A. L. (2013). Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. LANCET ONCOLOGY, 14(9), 863-872.

Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?
Townsend, N. C., Ruth, K., Al-Saleem, T., Horwitz, E. M., Sobczak, M., & Buyyounouski, M. K. (2013). Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(7), 812-819.

Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method
Zaorsky, N. G., Li, T., Devarajan, K., Horwitz, E. M., & Buyyounouski, M. K. (2012). Assessment of the American Joint Committee on Cancer Staging (Sixth and Seventh Editions) for Clinically Localized Prostate Cancer Treated With External Beam Radiotherapy and Comparison With the National Comprehensive Cancer Network Risk-Stratification Method. CANCER, 118(22), 5535-5543.

Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
Buyyounouski, M. K., Pickles, T., Kestin, L. L., Allison, R., & Williams, S. G. (2012). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(15), 1857-1863.

RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER
Pahlajani, N., Ruth, K. J., Buyyounouski, M. K., Chen, D. Yt., Horwitz, E. M., & Pollack, A. (2012). RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(5), 1949-1956.

DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR POSTOPERATIVE CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER
Michalski, J. M., Lawton, C., El Naqa, I., Ritter, M., O'Meara, E., & Menard, C. (2010). DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR POSTOPERATIVE CONFORMAL RADIATION THERAPY FOR PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(2), 361-368.

Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer
Murphy, C., Ruth, K. J., Buyyounouski, M. K., Heller, S., Weinberg, D., & Horwitz, E. M. (2013). Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S356-S356.

CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques
Chen, X., Xue, J., Chen, L., Buyyounouski, M. K., Horwitz, E. M., & Ma, C. (2013). CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S718-S718.

Toxicity and Biochemical Failure Following Image-Guided Prostate Intensity Modulated Radiation Therapy: Fiducial Markers Versus Electromagnetic Transponders
Chang, L., Li, T., Horwitz, E., Chen, D. Yt., Viterbo, R., & Buyyounouski, M. K. (2013). Toxicity and Biochemical Failure Following Image-Guided Prostate Intensity Modulated Radiation Therapy: Fiducial Markers Versus Electromagnetic Transponders. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S368-S369.

Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution
Murphy, C., Uzzo, R. G., Ruth, K. J., Viterbo, R., Plimack, E., & Greenberg, R. E. (2013). Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2), S378-S378.

Stratifying intermediate-risk patients for radiotherapy
Buyyounouski, M. K. (2013). Stratifying intermediate-risk patients for radiotherapy. NATURE REVIEWS UROLOGY, 10(8), 438-439.

Reduction of prostate intrafractional motion from shortening the treatment time
Li, J. S., Lin, M.-H., Buyyounouski, M. K., Horwitz, E. M., & Ma, C.-M. (2013). Reduction of prostate intrafractional motion from shortening the treatment time. PHYSICS IN MEDICINE AND BIOLOGY, 58(14), 4921-4932.

A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints
Ahmed, A. A., Egleston, B., Alcantara, P., Li, L., Pollack, A., & Buyyounouski, M. K. (2013). A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy and the Need for Age-Based Risk-Adapted Dose Constraints. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 86(4), 709-715.

Untitled Reply
Turaka, A., Buyyounouski, M. K., Horwitz, E. M., & Movsas, B. (2013). Untitled Reply. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 86(1), 6-7.

In reply to Cheung.
Turaka, A., Buyyounouski, M. K., Horwitz, E. M., & Movsas, B. (2013). In reply to Cheung. International journal of radiation oncology, biology, physics, 86(1), 6-7.

The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms
Stoyanova, R., Pahlajani, N. H., Egleston, B. L., Buyyounouski, M. K., Chen, D. Yt., & Pollack, A. (2013). The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. CANCER, 119(5), 1080-1088.

Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial
Pollack, A., Walker, G., Stoyanova, R., Khor, L., Horwitz, E., & Buyyounouski, M. (2012). Prospective Validation of Diagnostic Tumor Tissue Ki-67 as the Most Significant Predictor of Outcome in Men Treated for Prostate Cancer on a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S25-S26.

Primary Prostate Radiation Therapy: Where Are We Failing?
Huang, K. T., Walker, G., Stoyanova, R., SANDLER, K., Horwitz, E., & Pollack, A. (2012). Primary Prostate Radiation Therapy: Where Are We Failing?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S182-S182.

Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial
Stoyanova, R., Walker, G., SANDLER, K., Khor, L., Horwitz, E., & Pollack, A. (2012). Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy for Men With Prostate Cancer Treated on a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S60-S60.

Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)?
Martin, J. M., Sopka, D. M., Ruth, K. J., Buyyounouski, M. K., Kutikov, A., & Horwitz, E. M. (2012). Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low- and Intermediate-risk Prostate Cancer (CaP)?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S185-S186.

Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup Risk Categories
Townsend, N. C., Ruth, K., Buyyounouski, M., Kutikov, A., Viterbo, R., & Horwitz, E. M. (2012). Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup Risk Categories. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S183-S183.

A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry
Ahmed, A., Egleston, B., Alcantara, P., Pollack, A., Li, L., & Buyyounouski, M. K. (2012). A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy-based on Bladder Wall Dosimetry. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S418-S419.

Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy
Zaorsky, N. G., Buyyounouski, M. K., Li, T., & Horwitz, E. M. (2012). Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), E13-E17.

Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment
Klayton, T., Price, R., Buyyounouski, M. K., Sobczak, M., Greenberg, R., & Horwitz, E. M. (2012). Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 130-136.

Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer
Keller, L. Mm., Buyyounouski, M. K., Sopka, D., Ruth, K., Klayton, T., & Horwitz, E. M. (2012). Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer. UROLOGY, 80(2), 337-342.

Radiotherapy Treatment Planning for Testicular Seminoma
Wilder, R. B., Buyyounouski, M. K., Efstathiou, J. A., & Beard, C. J. (2012). Radiotherapy Treatment Planning for Testicular Seminoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(4), E445-E452.

A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update
Buyyounouski, M. K., Davis, B. J., Prestidge, B. R., Shanahan, T. G., Stock, R. G., & Horwitz, E. M. (2012). A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. BRACHYTHERAPY, 11(4), 299-305.

Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations
Hossain, M., Richardson, T., Buyyounouski, M. K., Schirmer, T., Noeske, R., & Ma, C. (2012). Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations. MEDICAL PHYSICS, 39(6), 3639-3640.

How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant?
Li, J. S., Buyyounouski, M., Horwitz, E., & Ma, C.-M. (2012). How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant?. MEDICAL PHYSICS, 39(6), 3933-3933.

Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate
Hossain, M., Schirmer, T., Richardson, T., Chen, L., Buyyounouski, M. K., & Ma, C. M. (2012). Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(1), 451-458.

Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy
Lubbe, W., Cohen, R., Sharma, N., Ruth, K., Peters, R., & Horwitz, E. (2012). Biochemical and clinical experience with real-time intraoperatively planned permanent prostate brachytherapy. BRACHYTHERAPY, 11(3), 209-213.

Testicular Cancer Clinical Practice Guidelines in Oncology
Motzer, R. J., Agarwal, N., Beard, C., Bhayani, S., Bolger, G. B., & Wilder, R. B. (2012). Testicular Cancer Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(4), 502-535.

An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee
Allen, A. M., Pawlicki, T., Dong, L., Fourkal, E., Buyyounouski, M., & Konski, A. A. (2012). An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. RADIOTHERAPY AND ONCOLOGY, 103(1), 8-11.

Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results
Turaka, A., Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., & Movsas, B. (2012). Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(3), E433-E439.

Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer
Klayton, T. L., Ruth, K., Horwitz, E. M., Uzzo, R. G., Kutikov, A., & Buyyounouski, M. K. (2011). Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. RADIOTHERAPY AND ONCOLOGY, 101(3), 508-512.

Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer
Boorjian, S. A., Karnes, R. J., Viterbo, R., Rangel, L. J., Bergstralh, E. J., & Buyyounouski, M. K. (2011). Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. CANCER, 117(13), 2883-2891.

INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
Sharma, N. K., Li, T., Chen, D. Y., Pollack, A., Horwitz, E. M., & Buyyounouski, M. K. (2011). INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 80(2), 437-444.

PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION: THE CENTRAL ROLE OF TUMOR STAGE AND RADIATION DOSE
Williams, S., Buyyounouski, M., Kestin, L., Duchesne, G., & Pickles, T. (2011). PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION: THE CENTRAL ROLE OF TUMOR STAGE AND RADIATION DOSE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 79(3), 724-731.

The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence After Radiotherapy for Prostate Cancer
Townsend, N. C., Ruth, K., Al-Saleem, T., Horwitz, E. M., Sobczak, M., & Buyyounouski, M. K. (2011). The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence After Radiotherapy for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S409-S410.

A Nomogram Predicting 5-year Probability of Cause Specific Survival from Biochemical Failure following Radiotherapy
Buyyounouski, M. K., Kestin, L., Duchesne, G., Pickles, T., Allison, R., & Williams, S. (2011). A Nomogram Predicting 5-year Probability of Cause Specific Survival from Biochemical Failure following Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S389-S389.

Aspirin Use Reduces the Risk of Biochemical Failure and Distant Metastases Following Post-Prostatectomy Radiotherapy
Cohen, R. J., Li, T., Horwitz, E. M., Peter, R., Uzzo, R. G., & Buyyounouski, M. K. (2011). Aspirin Use Reduces the Risk of Biochemical Failure and Distant Metastases Following Post-Prostatectomy Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S391-S392.

A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy
Bagshaw, H. P., Ruth, K., Horwitz, E. M., Chen, D., & Buyyounouski, M. K. (2011). A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S211-S211.

VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT for Treatment of Prostate Cancer
Lubbe, W. J., Price, R., Ruth, K., Cherian, G., Kutikov, A., & Horwitz, E. (2011). VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT for Treatment of Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S446-S446.

Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer
Oh, J., Deasy, J., Stoyanova, R., Saleh, Z., Buyyounouski, M., & Pollack, A. (2011). Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a Randomized Hypofractionation Trial for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S156-S157.

Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT
Li, J., Buyyounouski, M. K., Lin, M., Horwitz, E. M., & Ma, C. (2011). Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S391-S391.

Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer
Pollack, A., Walker, G., Buyyounouski, M., Horwitz, E., Price, R., & Ma, C. (2011). Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S1-S1.

Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial
Hu, J. J., Stoyanova, R., Deasy, J. O., Chung, R., Martin, E., & Pollack, A. (2011). Genetic Polymorphisms of DNA Repair and Inflammatory Responses as Determinants of Late Toxicity in Prostate Cancer Patients Who Received Radiotherapy in a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S109-S110.

Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment
Klayton, T. L., Price, R., Buyyounouski, M. K., Sobczak, M., Greenberg, R. E., & Horwitz, E. M. (2011). Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S101-S101.

Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial
Jean-Pierre, P., Stoyanova, R., Penedo, F., Antoni, M., Abramowitz, M., & Pollack, A. (2011). Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With Conventional versus Hypofractionated Intensity Mediated Radiotherapy: A Phase III Hypofractionation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S667-S667.

Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT
Canter, D., Greenberg, R. E., Horwitz, E. M., Kutikov, A., Li, J., & Boorjian, S. A. (2010). Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT. CANADIAN JOURNAL OF UROLOGY, 17(5), 5365-5369.

STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: REPORT OF THE ASTRO EMERGING TECHNOLOGY COMMITTEE
Buyyounouski, M. K., Balter, P., Lewis, B., D'Ambrosio, D. J., Dilling, T. J., & Wallner, P. E. (2010). STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: REPORT OF THE ASTRO EMERGING TECHNOLOGY COMMITTEE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(1), 3-10.

Androgen Deprivation Therapy in High-Risk Prostate Cancer
Buyyounouski, M. K. (2010). Androgen Deprivation Therapy in High-Risk Prostate Cancer. ONCOLOGY-NEW YORK, 24(9), 806-809.

RADIOTHERAPY PSA nadir predicts long-term mortality
Buyyounouski, M. K. (2010). RADIOTHERAPY PSA nadir predicts long-term mortality. NATURE REVIEWS CLINICAL ONCOLOGY, 7(4), 188-190.

STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE, LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: REPORT OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY EMERGING TECHNOLOGY COMMITTEE
Buyyounouski, M. K., Price, R. A., Harris, E. Er., Miller, R., Tome, W., & Wallner, P. E. (2010). STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE, LOW- TO INTERMEDIATE-RISK PROSTATE CANCER: REPORT OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY EMERGING TECHNOLOGY COMMITTEE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(5), 1297-1304.

An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy
Sharma, N. K., Cohen, R. J., Eade, T. N., Buyyounouski, M. K., Uzzo, R. G., & Horwitz, E. M. (2010). An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. BRACHYTHERAPY, 9(2), 126-130.

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population
Kaplan, D. J., Boorjian, S. A., Ruth, K., Egleston, B. L., Chen, D. Yt., & Giri, V. N. (2010). Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population. BJU INTERNATIONAL, 105(3), 334-337.

Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam Radiation Therapy Prostate Cancer
Klayton, T. L., Ruth, K., Horwitz, E. M., Uzzo, R. G., Kuritzky, N. K., & Buyyounouski, M. K. (2010). Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam Radiation Therapy Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S334-S334.

Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with Androgen Deprivation Therapy: The Fox Chase Experience
Sopka, D. M., Li, T., Horwitz, E. M., Chen, D. Yt., & Buyyounouski, M. K. (2010). Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with Androgen Deprivation Therapy: The Fox Chase Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S351-S352.

Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer
Husain, Z. A., Sharma, N. K., Hanlon, A. L., Buyyounouski, M. K., Mirmiran, A., & Feigenberg, S. J. (2010). Low Pretreatment PET SUV Predicts for Increased Local Failure following Stereotactic Body Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S525-S525.

The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT
Keller, L. M., Ruth, K., Horwitz, E. M., Pollack, A., Watkins-Bruner, D., & Buyyounouski, M. K. (2010). The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S596-S597.

Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy
Zietman, A. L., HUNT, D., Kaufman, D. S., Uzzo, R., Wu, C., & Shipley, W. U. (2010). Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S31-S32.

A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System
Li, J., Jin, L., Horwitz, E. M., Buyyounouski, M. K., Price, R. A., & Ma, C. (2010). A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S701-S702.

Interval to Biochemical Failure is Highly Prognostic for Distant Metastases and Mortality after Salvage Radiation Therapy
Buyyounouski, M. K., Li, T., Turaka, A., Chen, D. Yt., & Horwitz, E. M. (2010). Interval to Biochemical Failure is Highly Prognostic for Distant Metastases and Mortality after Salvage Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S348-S348.

Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial
Turaka, A., Zhu, F., Buyyounouski, M. K., Horwitz, E. M., Watkins-Bruner, D., & Pollack, A. (2010). Conventional versus Hypofractionated IMRT: Results of Late GI and GU Toxicity and Quality of Life from a Phase III Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S67-S67.

The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience
Horwitz, E. M., Sharma, N. K., Ruth, K., Silverman, J. S., Buyyounouski, M. K., & Uzzo, R. G. (2010). The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S333-S334.

GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY
Li, J. S., Jin, L., Pollack, A., Horwitz, E. M., Buyyounouski, M. K., & Ma, C.-M. (2009). GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(5), 1613-1620.

Androgen Deprivation Therapy and Prostate Cancer Duration
Williams, S. G., Pickles, T., & Buyyounouski, M. K. (2009). Androgen Deprivation Therapy and Prostate Cancer Duration. JOURNAL OF CLINICAL ONCOLOGY, 27(34), E228-E228.

Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value
Feigenberg, S. J., Sharma, N., Yu Jian Q, J. Q., Lally, B., Borghaei, H., & Movsas, B. (2009). Optimal PET response following stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is closely related to the pre-SBRT maximum standard uptake value. JOURNAL OF THORACIC ONCOLOGY, 4(9), S734-S734.

Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) for lung tumors
Feigenberg, S. J., Sharma, N., Yu, J. Q., Buyyounouski, M., Borghaei, H., & Movsas, B. (2009). Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 4(9), S943-S943.

Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don't? The Lawrentschuk/Fleshner Article Reviewed
Buyyounouski, M. K. (2009). Surveillance for Stage I Seminoma: Better the Devil You Know Than the Devil You Don't? The Lawrentschuk/Fleshner Article Reviewed. ONCOLOGY-NEW YORK, 23(9), 762-764.

RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER
Lawton, C. Af., Michalski, J., El-Naqa, I., Buyyounouski, M. K., Lee, W. R., & Seider, M. (2009). RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 74(2), 383-387.

Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage
Wang, L., Hayes, S., Paskalev, K., Jin, L., Buyyounouski, M. K., & Feigenberg, S. (2009). Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: Evaluation of the impact on daily dose coverage. RADIOTHERAPY AND ONCOLOGY, 91(3), 314-324.

Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results
Turaka, A., Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Greenberg, R. E., & Movsas, B. (2009). Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio and biochemical failure in patients with localized prostate cancer: Long-term results. JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens Editorial Comment
Kaplan, D. J., Crispen, P. L., Greenberg, R. E., Chen, D. Y., Viterbo, R., & Uzzo, R. G. (2009). Residual Prostate Cancer After Radiotherapy: A Study of Radical Cystoprostatectomy Specimens Editorial Comment. JOURNAL OF UROLOGY, 181(5), 2111-2112.

Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men
Giri, V. N., Egleston, B., Ruth, K., Uzzo, R. G., Chen, D. Yt., & Kittles, R. (2009). Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. CANCER PREVENTION RESEARCH, 2(3), 244-250.

Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer
Sharma, N. K., Ruth, K. J., Boorjian, S. A., Uzzo, R. G., Buyyounouski, M. K., & Horwitz, E. M. (2009). Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for Low-intermediate Risk Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S313-S313.

Defining Biochemical Failure following Salvage Radiotherapy
Lubbe, W. J., Ruth, K., Devarajan, K., Horwitz, E. M., Boorjian, S., & Buyyounouski, M. K. (2009). Defining Biochemical Failure following Salvage Radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S330-S330.

A Potential Outcomes Framework to Determine Whether Age and Medical Co-morbidities Predict Who is Harmed by Combined Androgen Deprivation Therapy
Silverman, J. S., Egleston, B., Horwitz, E. M., Chen, D. Yt., & Buyyounouski, M. K. (2009). A Potential Outcomes Framework to Determine Whether Age and Medical Co-morbidities Predict Who is Harmed by Combined Androgen Deprivation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S326-S326.

Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?
Cohen, R. J., Sharma, N. K., Ruth, K., Buyyounouski, M. K., Li, J., & Horwitz, E. M. (2009). Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S298-S298.

Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
Buyyounouski, M. K., Pickles, T., Kestin, L., Allison, R., & Williams, S. G. (2009). Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S103-S104.

Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate Risk Prostate Cancer is an Independent Predictor of Biochemical and Clinical Outcome
Horwitz, E. M., Ruth, K. J., Sharma, N. K., Chen, D. Yt., Buyyounouski, M. K., & Uzzo, R. G. (2009). Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate Risk Prostate Cancer is an Independent Predictor of Biochemical and Clinical Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S301-S301.

Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial
Pollack, A., Li, T., Buyyounouski, M., Horwitz, E., Price, R., & Ma, C. (2009). Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75(3), S81-S82.

DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?
D'Ambrosio, D. J., Li, T., Horwitz, E. M., Chen, D. Yt., Pollack, A., & Buyyounouski, M. K. (2008). DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(5), 1402-1407.

Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens
Kaplan, D. J., Crispen, P. L., Greenberg, R. E., Chen, D. Yt., Viterbo, R., & Uzzo, R. G. (2008). Residual prostate cancer after radiotherapy: A study of radical cystoprostatectomy specimens. UROLOGY, 72(3), 654-658.

Comment on dose escalation and biochemical failure in prostate cancer: In regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70 : 67-74) - In reply to Drs. Schultz and Kagan
Pollack, A., Eade, T. M., Horwitz, E. M., Buyyounouski, M. K., & Hanks, G. E. (2008). Comment on dose escalation and biochemical failure in prostate cancer: In regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70 : 67-74) - In reply to Drs. Schultz and Kagan. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(4), 1288-1289.

A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or I-125 permanent implant
Eade, T. N., Horwitz, E. M., Ruth, K., Buyyounouski, M. K., D'Ambrosio, D. J., & Pollack, A. (2008). A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or I-125 permanent implant. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(2), 338-345.

Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
D'Ambrosio, D. J., Ruth, K., Horwitz, E. M., Chen, D. Yt., Pollack, A., & Buyyounouski, M. K. (2008). Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?. UROLOGY, 71(5), 938-941.

Influence of local tumor control on distant metastases and cancer related mortality after external, beam radiotherapy for prostate cancer - Editorial comment
Buyyounouski, M. K. (2008). Influence of local tumor control on distant metastases and cancer related mortality after external, beam radiotherapy for prostate cancer - Editorial comment. JOURNAL OF UROLOGY, 179(4), 1373-1373.

How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
D'Ambrosio, D. J., Ruth, K., Horwitz, E. M., Uzzo, R. G., Pollack, A., & Buyyounouski, M. K. (2008). How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(5), 1487-1491.

Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance
Williams, S. G., Buyyounouski, M. K., Pickles, T., Kestin, L., Martinez, A., & Duchesne, G. M. (2008). Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(4), 1169-1175.

Commentary on dose escalation and biochemical failure in prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68 : 682-689) - In reply
Pollack, A., Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., & Hanks, G. E. (2008). Commentary on dose escalation and biochemical failure in prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68 : 682-689) - In reply. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(2), 645-646.

Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue
Buyyounouski, M. K., Li, T., Al-Saleem, T., Horwitz, E., Konski, A., & Pollack, A. (2008). Predicting local persistence of intermediate and high-risk prostate cancer using percentage of adenocarcinoma in pretreatment biopsy tissue. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S321-S322.

Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., & Pollack, A. (2008). Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(1), 59-66.

Low morbidity and excellent local control using image guided stereotactic body radiotherapy (IGSBRT) for lung tumors
Sharma, N. K., Ruth, K., Konski, A. A., Buyyounouski, M. K., Nicolaou, N., & Feigenberg, S. J. (2008). Low morbidity and excellent local control using image guided stereotactic body radiotherapy (IGSBRT) for lung tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S454-S454.

Gains from real-time prostate motion monitoring during external beam radiation therapy
Li, J., Jin, L., Horwitz, E., Buyyounouski, M., Pollack, A., & Ma, C. (2008). Gains from real-time prostate motion monitoring during external beam radiation therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S287-S288.

The optimum duration of combination androgen deprivation therapy (ADT) with prostate cancer radiotherapy: Determining the duration-benefit relationship from multi-institutional analysis
Pickles, T., Williams, S. G., Buyyounouski, M. K., Kestin, L. L., & Duchesne, G. M. (2008). The optimum duration of combination androgen deprivation therapy (ADT) with prostate cancer radiotherapy: Determining the duration-benefit relationship from multi-institutional analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S73-S73.

The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
Abramowitz, M. C., Li, T., Buyyounouski, M. K., Ross, E., Uzzo, R. G., & Horwitz, E. M. (2008). The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. CANCER, 112(1), 55-60.

Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage?
Williams, S. G., Pickles, T., Kestin, L., Buyyounouski, M., Martinez, A., & Duchesne, G. (2008). Androgen deprivation therapy plus hypofractionated prostate radiotherapy-are we castrating the radiobiological advantage?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S73-S74.

Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy?
Silverman, J. S., Ruth, K., Horwitz, E. M., Pollack, A., Chen, D. Yt., & Buyyounouski, M. K. (2008). Radiation therapy for high risk prostate cancer: Do patients 70 years or older benefit from combined androgen deprivation therapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S75-S76.

Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms
Pahlajani, N. H., Egleston, B. L., Buyyounouski, M. K., Chen, D. Yt., Horwitz, E., & Pollack, A. (2008). Estimating gains in biochemical outcome from various durations of androgen deprivation in patients treated with dose escalated radiotherapy for prostate cancer using two nomograms. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S54-S54.

PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition
Horwitz, E. M., Ruth, K., Uzzo, R. G., Buyyounouski, M. K., Wong, Y., & Pollack, A. (2008). PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT or IMRT using the Phoenix definition. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(1), S135-S136.

Prostate cancer risk assessment program: A 10-year update of cancer detection
Giri, V. N., Beebe-Dimmer, J., Buyyounouski, M., Konski, A., Feigenberg, S. J., & Watkins-Bruner, D. (2007). Prostate cancer risk assessment program: A 10-year update of cancer detection. JOURNAL OF UROLOGY, 178(5), 1920-1924.

Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. CANCER, 110(1), 68-80.

What dose of external-beam radiation is high enough for prostate cancer?
Eade, T. N., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Hanks, G. E., & Pollack, A. (2007). What dose of external-beam radiation is high enough for prostate cancer?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 68(3), 682-689.

Daily localization for prostate bed patients based on surgical clips
Paskalev, K., Horwitz, E., Price, R., Feigenberg, S., Buyyounouski, M., & Pollack, A. (2007). Daily localization for prostate bed patients based on surgical clips. MEDICAL PHYSICS, 34(6), 2381-2382.

Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer
Wang, L., Jin, L., Hayes, S., Paskalev, K., Buyyounouski, M., & Feigenberg, S. (2007). Dosimetric comparison of 4D and 3 multi-phase CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. MEDICAL PHYSICS, 34(6), 2384-2384.

Surface smoothing of a tubular structure using a non-shrinking algorithm
Chen, Y., Paskalev, K., Horwitz, E., Price, R., Buyyounouski, M., & Pollack, A. (2007). Surface smoothing of a tubular structure using a non-shrinking algorithm. MEDICAL PHYSICS, 34(6), 2637-2637.

Do stranded seeds improve the quality of permanent prostate seed implant?
Li, J., Horwitz, E., Buyyounouski, M., McNeeley, S., Crawford, K., & Ma, C. (2007). Do stranded seeds improve the quality of permanent prostate seed implant?. MEDICAL PHYSICS, 34(6), 2330-2330.

Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate
Eade, T. N., Al-Saleem, T., Horwitz, E. M., Buyyounouski, M. K., Chen, D. Yt., & Pollack, A. (2007). Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. CANCER, 109(10), 2011-2015.

Radiation dose and late failures in prostate cancer
Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). Radiation dose and late failures in prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 67(4), 1074-1081.

The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
D'Ambrosio, D. J., Hanlon, A. L., Al-Saleem, T., Feigenberg, S. J., Horwitz, E. M., & Buyyounouski, M. K. (2007). The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 67(4), 1082-1087.

FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure
Feigenberg, S., Yu, J. Qm., Eade, T. N., Buyyounouski, M., Wang, L., & Movsas, B. (2007). FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S479-S480.

Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, E. M., & Pollack, A. (2007). Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. CANCER, 109(1), 41-47.

A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes
Morgan, P. B., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2007). A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: Toxicity and outcomes. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S319-S319.

Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer
Sharma, N. K., Li, T., Horwitz, E. M., Pollack, A., & Buyyounouski, M. K. (2007). Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S10-S10.

Does total treatment duration affect outcome in prostate cancer treated with radiotherapy?
D'Ambrosio, D. J., Horwitz, T. Lem., Chen, D., Pollack, A., & Buyyounouski, M. K. (2007). Does total treatment duration affect outcome in prostate cancer treated with radiotherapy?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S176-S176.

A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy
Buyyounouski, M. K., Li, T., Watkins-Bruner, D., Horwitz, E. M., & Pollack, A. (2007). A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S7-S8.

Effect of target smoothness on treatment planning for prostate IMRT
Chen, Y., Paskalev, K., Horwitz, E., Price, R., Buyyounouski, M., & Pollack, A. (2007). Effect of target smoothness on treatment planning for prostate IMRT. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3), S649-S649.

Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer
Price, R. A., Hannoun-Levi, J.-M., Horvvitz, E., Buyyounouski, M., Ruth, K. J., & Pollack, A. (2006). Impact of pelvic nodal irradiation with intensity-modulated radiotherapy on treatment of prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(2), 583-592.

Daily changes in seminal vesicle location during treatment of prostate carcinoma
McNeeley, S., Paskalev, K., Buyyounouski, M., & Ma, C. (2006). Daily changes in seminal vesicle location during treatment of prostate carcinoma. MEDICAL PHYSICS, 33(6), 2030-2030.

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
Pollack, A., Hanlon, A. L., Horwitz, E. M., Feigenberg, S. J., Konski, A. A., & Price, R. A. (2006). Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64(2), 518-526.

CT-based daily localization of prostate patients: Anatomy vs. implanted markers
Paskalev, K., Feigenberg, S., McNeeley, S., Horwitz, E., Price, R., & Alan, P. (2006). CT-based daily localization of prostate patients: Anatomy vs. implanted markers. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S621-S621.

Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis
Morgan, P. B., Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., Uzzo, R. G., & Pollack, A. (2006). Increasing radiotherapy dose for prostate cancer reduces a late wave of distant metastasis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S9-S10.

The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause
Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., & Pollack, A. (2006). The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S206-S207.

Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy
Kirichenko, A. V., Ruth, K., Horwitz, E. M., Buyyounouski, M. K., Feigenberg, S. J., & Pollack, A. (2006). Intensity modulated radiation therapy for prostate cancer: Preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S326-S326.

Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy
Eade, T. N., Ruth, K., D'Ambrosio, D. J., Feigenberg, S. J., Buyyounouski, M. K., & Horwitz, E. M. (2006). Comparison of outcomes in low risk prostate cancer: I-125 seed brachytherapy vs. intensity modulated radiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S60-S61.

Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation
Pahlajani, N. H., Ruth, K., Horwitz, E. M., Buyyounouski, M. B., Chen, D. Y., & Pollack, A. (2006). Smoking and its relationship to GU and GI toxicity in prostate cancer patients treated with radiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S317-S317.

Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis
Hanlon, A. L., Horwitz, E. M., Buyyounouski, M. K., & Pollack, A. (2006). Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S346-S347.

Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation
D'Ambrosio, D. J., Ruth, K., Buyyounouski, M. K., Horwitz, E. M., Uzzo, R. G., & Pollack, A. (2006). Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S334-S334.

The nadir+2 definition of biochemical failure predicts for overall survival
Abramowitz, M. C., Li, T., Ross, E., Buyyounouski, M., Uzzo, R. G., & Horwitz, E. M. (2006). The nadir+2 definition of biochemical failure predicts for overall survival. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66(3), S207-S208.

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
Buyyounouski, M. K., Hanlon, A. L., Eisenberg, D. F., Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2005). Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(5), 1455-1462.

Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
Buyyounouski, M. K., Hanlon, A. L., Horwitz, E. M., Uzzo, R. G., & Pollack, A. (2005). Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 61(5), 1291-1298.

In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046.
Buyyounouski, M. K., Hanlon, A. L., Price, R. A., Horwitz, E. M., Feigenberg, S. J., & Pollack, A. (2004). In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046. International journal of radiation oncology, biology, physics, 60(5), 1664-1665.

The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
Buyyounouski, M. K., Horwitz, E. M., Uzzo, R. G., Price, R. A., McNeeley, S. W., & Pollack, A. (2004). The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 59(5), 1383-1391.

Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
Buyyounouski, M. K., Horwitz, E. M., Price, R. A., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2004). Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(3), 743-749.

Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database.
Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., & Pollack, A. (2004). Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. journal of urology, 171(3), 1246-1247.

Positive prostate biopsy laterality and implications for staging
Buyyounouski, M. K., Horwitz, E. M., Hanlon, A. L., Uzzo, R. G., Hanks, G. E., & Pollack, A. (2003). Positive prostate biopsy laterality and implications for staging. UROLOGY, 62(2), 298-303.